Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction

IJC Heart and Vasculature

Volumn 10, Issue , 2016, Pages 8-12

  Mazhar, Jawad ^a   Mashicharan, Mary ^a   Farshid, Ahmad ^a,b  

^a CANBERRA HOSPITAL   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

No reflow; Primary percutaneous coronary intervention; Slow coronary flow; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY BLOOD FLOW; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; SCORING SYSTEM; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS; TREATMENT OUTCOME;

EID: 84947982903     PISSN: 23529067     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcha.2015.11.002     Document Type: Article

References (27)

1. Steg P.G., James S.K., Atar D., Badano L.P., Blomstrom-Lundqvist C., Borger M.A., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012, 33(20):2569-2619.
2. Harrison R.W., Aggarwal A., Ou F.S., Klein L.W., Rumsfeld J.S., Roe M.T., et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am. J. Cardiol. 2013, 111(2):178-184.
3. Schwartz B.G., Kloner R.A. Coronary no reflow. J. Mol. Cell. Cardiol. 2012, 52(4):873-882.
4. Jaffe R., Dick A., Strauss B.H. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc. Interv. 2010, 3(7):695-704.
5. Aung Naing K., Li L., Su Q., Wu T. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst. Rev. 2013, 6:CD009503.
6. Gick M., Jander N., Bestehorn H.P., Kienzle R.P., Ferenc M., Werner K., et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005, 112(10):1462-1469.
7. Kelbaek H., Terkelsen C.J., Helqvist S., Lassen J.F., Clemmensen P., Klovgaard L., et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J. Am. Coll. Cardiol. 2008, 51(9):899-905.
8. Stone G.W., Webb J., Cox D.A., Brodie B.R., Qureshi M., Kalynych A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005, 293(9):1063-1072.
9. Chan W., Stub D., Clark D.J., Ajani A.E., Andrianopoulos N., Brennan A.L., et al. Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. Am. J. Cardiol. 2012, 109(4):478-485.
10. Choo E.H., Kim P.J., Chang K., Ahn Y., Jeon D.S., Lee J.M., et al. The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality. Coron. Artery Dis. 2014.
11. Gibson C.M., Schomig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004, 109(25):3096-3105.
12. Gibson C.M., de Lemos J.A., Murphy S.A., Marble S.J., McCabe C.H., Cannon C.P., et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001, 103(21):2550-2554.
13. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., et al. Third universal definition of myocardial infarction. Eur. Heart J. 2012, 33(20):2551-2567.
14. Ndrepepa G., Tiroch K., Fusaro M., Keta D., Seyfarth M., Byrne R.A., et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 2010, 55(21):2383-2389.
15. Wu X., Mintz G.S., Xu K., Lansky A.J., Witzenbichler B., Guagliumi G., et al. The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc. Interv. 2011, 4(5):495-502.
16. Ruiz-Garcia J., Lerman A., Weisz G., Maehara A., Mintz G.S., Fahy M., et al. Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. EuroIntervention 2012, 8(8):929-938.
17. Dong-bao L., Qi H., Zhi L., Shan W., Wei-ying J. Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction. Clin. Cardiol. 2010, 33(12):E7-12.
18. Suenari K., Shiode N., Shirota K., Ishii H., Goto K., Sairaku A., et al. Predictors and long-term prognostic implications of angiographic slow/no-flow during percutaneous coronary intervention for acute myocardial infarction. Intern. Med. (Tokyo, Japan) 2008, 47(10):899-906.
19. O'Gara P.T., Kushner F.G., Ascheim D.D., Casey D.E., Chung M.K., de Lemos J.A., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 61(4):e78-140.
20. Chen Y., Wang C., Yang X., Wang L., Sun Z., Liu H., et al. Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Heart Vessels 2012, 27(3):243-249.
21. Gibson C.M., Dotani M.I., Murphy S.A., Marble S.J., Dauterman K.W., Michaels A.D., et al. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Am. Heart J. 2002, 144(1):130-135.
22. Limbruno U., De Carlo M., Pistolesi S., Micheli A., Petronio A.S., Camacci T., et al. Distal embolization during primary angioplasty: histopathologic features and predictability. Am. Heart J. 2005, 150(1):102-108.
23. Henriques J.P., Zijlstra F., Ottervanger J.P., de Boer M.J., van 't Hof A.W., Hoorntje J.C., et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur. Heart J. 2002, 23(14):1112-1117.
24. Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. J. Am. Coll. Cardiol. 2009, 54(4):281-292.
25. Carrick D., Oldroyd K.G., McEntegart M., Haig C., Petrie M.C., Eteiba H., et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J. Am. Coll. Cardiol. 2014, 63(20):2088-2098.
26. Freixa X., Belle L., Joseph L., Tanguay J.F., Souteyrand G., LA P.L., et al. Immediate vs. delayed stenting in acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention 2013, 8(10):1207-1216.
27. Kelbaek H., Engstrom T., Ahtarovski K.A., Lonborg J., Vejlstrup N., Pedersen F., et al. Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study. EuroIntervention 2013, 8(10):1126-1133.